Condition: Metastatic Pancreatic Ductal Adenocarcinoma · Sponsor: Belgian Group of Digestive Oncology
A non-comparative randomized phase 2 study, evaluating the efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for metastatic pancreatic ductal adenocarcinoma (PDAC), progressive after Gemcitabine-Abraxane or Gemcitabine monotherapy
This description comes directly from the study's public registry record.
Lina Dewever · +32 (0) 479 36 63 82 · lina.dewever@bgdo.org
Always discuss trial participation with your own doctor first.
| UZ Antwerpen | Antwerp, Antwerp, Belgium | Recruiting |
| ULB Erasme | Brussels, Brussels Capital, Belgium | Recruiting |
| Cliniques Universitaires Saint-Luc UCL | Brussels, Brussels Capital, Belgium | Recruiting |
| CHC MontLégia | Liège, Liège, Belgium | Recruiting |
| AZ St-Lucas | Bruges, West-Vlaanderen, Belgium | Not Yet Recruiting |
| AZ Imelda | Bonheiden, Belgium | Recruiting |
| Grand Hopital de Charleroi | Charleroi, Belgium | Recruiting |
| AZ Maria Middelares | Ghent, Belgium | Recruiting |
| University Hospital Ghent | Ghent, Belgium | Recruiting |
| Pôle Hospitalier Jolimont (HELORA) | Haine-Saint-Paul, Belgium | Recruiting |
| CHU Ambroise Paré | Mons, Belgium | Recruiting |
| CHR Namur | Namur, Belgium | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05472259